Vilobelimab’s effect on mortality in severe COVID-19 ARDS patients: Phase 3 RCT

Résumé fourni par la source

Introduction: A C5a-specific mAb, vilobelimab (VILO), in a Phase 3 randomized, double-blind, placebo (P)-controlled study showed significant reduction in 28-d all-cause mortality in critically ill COVID-19 patients (pt) (Vlaar APJ et al. Lancel Respir Med 2022;10(12):1137-46). Aims and Objectives: To compare mortality worldwide and by region in severe ARDS COVID-19 pt treated with VILO vs P. Methods: COVID-19 pt (N=368; VILO n=177, P n=191) were intubated within 48 hrs before 6, 800mg infusions of VILO or P on top of standard-of-care. Prespecified and posthoc analyses were performed worldwide and by region [Western Europe (WE), South America (SA), Russia/South Africa (RSA)] for mortality in severe ARDS pt with PaO2/FiO2<100 mmHg. Results: Median age (VILO 58 vs P 57 yrs), sex (~70% male) and severe ARDS pt were similar (VILO n=43, 24.3%; P n=55, 28.8%). VILO significantly reduced relative all-cause 28-d mortality worldwide in severe ARDS pt by 32.8% (HR 0.55; 95% CI:0.30-0.98;P=0.044). By region, VILO showed a nonsignificant 28-d mortality reduction trend (HR 0.37; 95% CI:0.11-1.22;P=0.058) in WE but SA (HR 1.03; 95% CI:0.040-2.70;P=0.944) and RSA (HR 0.37; 95% CI:0.11-1.22;P=0.102) showed lesser effects likely due to a younger P group median age in SA (VILO 50.0 vs P 45.5 yrs) and small numbers of severe ARDS pt in RSA. Treatment-emergent AEs, serious AEs and infection incidence per 100 pt days were equal per group with no meningococcal infections. Conclusion: Vilobelimab demontrated a significant worldwide reduction in all-cause mortality in severe ARDS COVID-19 pt with detected differences in three prespecified regions which may have been impacted by low pt numbers and an uneven age distribution in SA.

Ce résumé expose les affirmations des auteurs. BNTIC ne l’interprète pas comme une validation indépendante des résultats.